Applying the most accurate HPV detection methods presently available a HPV prevalence of about 26% can be expected in squamous cell carcinomas of the head and neck, as we have shown earlier. In this study, we investigated the presence of detectable HPV DNA in neck metastases (NM) of this tumor entity by the same methods. Furthermore, in eight cases the correlation of primary tumor (PT) and NM of the same patients could be analyzed. ,,Hot start" polymerase chain reaction employing type specific primers as well as consensus primer pairs followed by Southern blot hybridization of the PCR products was performed on DNA extracted from fresh frozen material of 27 NM and 9 PT samples.
HPV type could not yet be identified. In 3/4 (75%) HPV positive PT cases the investigated NM samples showed detectable HPV DNA as well, and in 4/5 (80%) cases both NM and PT samples of the same patients were HPV negative. The prevalence of HPV DNA in PT of patients that develop resectable NM seems to be higher than in those that do not, though the high prevalence rate might also be due to the small number of cases investigated. NM show detectable HPV DNA in 48% of the cases reflecting an association of HPV infection and progression to metastases. The presence of HPV 16 DNA in 38.8% of the positive NM cases points to a special role of this ,,high risk" HPV type also in developing NM. The high rate of HPV positives that could not be identified might be due to integration of the viral DNA into the genome thought to be a further sign of tumor progression. The strong correlation of the HPV status in PT and NM of the same patients (77.8%) supports the hypothesis that HPV specifically infects the tumor cell.
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The degree of cell surface sialylation of metastases of head and neck cancer F Riedel, W. Bergler, A. Baker-Schreyer, K. G6tte, G. Petroianu, K.
Hormann, Dept. of ORL, Mannheim, University of Heidelberg, Germany Purpose: The sialoglycans and the degree of sialylation on the cell surface are of increasing interest because of the possible contribution to metastasis and invasion. Primary tumors and metastasis may differ in the degree of sialylation. Material and methods: Cell surface sialylation of 30 lymph node metastases and 30 squamous cell carcinomas of the head and neck was determined by a new histobiochemical assay on cryostat sections which is based on the enzymatic introduction of a fluorescence-labelled sialic acid (CMP-9-fluoresceinyl-NeuAc) into lactosaminyl type (Gal 3 1-4 GlcNAc) oligosaccharide chains of cell surface glycoproteins by a-2,6-sialyltransferase. To compare degree of sialylation with the total amount of sialylation sites a pretreatment with sialidase for desialylation was required.
Results: We observed a significant (p=O.001) higher amount of lactosaminyl type binding sites for sialic acid on metastases compared to the primary tumors. Pretreatment with sialidase could detect a significant amount of sialylation on primaries and metastases, showing a lower degree of sialylation in metastases. In primary tumors no correlation was seen between the amount of binding sites and tumor localization, TNM-stage or histological grading of the tumors. Conclusions: A higher degree of sialic acid free lactosaminyl glycans on the cell surface of head and neck tumors seems to be correlated with the occurence of metastasis. Approximately 75% of the primary tumors were found to be telomerase positive. In all histological positive nodes we detected telomerase activity. Interestingly, telomerase activity was also present in 90% of the histological negative lymph nodes. The latter may be due to activated lymphocytes which are known to be telomerase active. By correlating clinical and molecularbiological datas we will discuss our conclusion that the detection of telomerase activity in primary head and neck tumors is not necessarily a reliable predictor for the metastastic potential of these tumors. Introduction: Patients with head and neck squamous cell carcinoma (HNSCC) are usually followed-up clinically. During the follow-up it is difficult to detect distant metastases at early stages, while a locoregional tumor progression sometimes can be seen quite easily. Cyfra 21-1, a novel tumor marker, was shown to correlate with tumor size in HNSCC. Therefore, it seemed worthwhile elucidating a possible role of cyfra 21-1 in the metastastic progression of HNSCC. Methods: During the followup, we compared the course of cyfra 21-1 values in sera of HNSCC patients with distant metastases (n=18) and without distant metastases (n=3 10). Results: 17 of 18 patients with distant metastases had cyfra 21-1 values above the threshold of 2.2 ng/ml. Initially high or suddenly rising cyfra 21-1 values during the follow-up mostly preceded or coincided with the detection of distant metastases. Conclusions: The presented results indicate that cyfra 21-1 may be useful in the early diagnosis of distant metastases in HNSCC. T'his may influence therapeutical decisions that sometimes go along with disfiguring surgical procedures, e.g. laryngectomy. The early detection of distant metastases may avoid unnecessary suffering for these patients, who may then profit from an early cooperation between different clinical departments and alternative therapy plans.
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Follow-up of patients with carcinoma of head and neck using the tumor marker Cyfra 21-1 for early detection of recurrent disease I. Doweck, M. Barak, N. Uri, E. Greenberg, Dept. of ORL, Biochemistry Research Unit, Carmel Medical Center, Haifa, Israel Cyfra 21-1 was reported as a new potential tumor marker for squamous cell carcinoma ofhead and neck. In the present study we evaluated the additional value of Cyfra 21-1 in the follow up of patients with head and neck cancer. The study included 38 patients with primary detection of head and neck carcinoma, who were followed up for at least one year during the different treatment regimens. Patients were followed every month for the first year after diagnosis and every three months for the following years.
Cyfra 21-1 was determined periodically using an Elisa kit. Clinical suspicion of recurrence or a significant increase in the Cyfra 21-1 level (>25%) was further investigated by histologicaltbiopsy.
Thirty eight patients were followed using Cyfra 21-1. Out of 38 patients, 12 had recurrent disease. In 10 of these patients (83%), Cyfra 21-1 was elevated before or concomitantly with the clinical detection of the recurrence. 26 patients had no clinical evidence of disease during the evaluation. In 20 of them (77%), there was no significant elevation in the marker levels during follow up. Elevated levels of the marker without clinical evidence of disease can be attributed to the mean lead time of the marker as compared to clinical appearance ofthe disease. Conclusion: Cyfra 21-1 was found as an additional useful tool for the follow up ofpatients with carcinoma ofhead and neck. Introduction: Lymph node metastases are often difficult to detect.
However, if present -detected or undetected -they severely reduce the patient's chances of healing. A controversy evolves around the useflIness of elective neck dissection. The aim of the present study was to determine how often the posttherapeutic Nstatus had to be changed due to a histopathological diagnosis differing from No. In this respect the validity of the imaging procedures in staging was investigated. Patients and methods: From April 1996 until May 1997 12 patients with squamous cell carcinomas of the head and neck underwent an elective neck dissection. The tumors were located in the oral cavity (3), oropharynx (2), hypopharynx (1), and larynx (6). All patients were staged with ultra sound. Additionally 7 patients had a CT, 4 an MRI, and 1 patient had a CT and an MRI of the neck. Results: The histopathological diagnosis was NO in 9 cases, Nl in 2, and N2b in 1 patient. Conclusions: In one quarter of the patients lymph node metastases were present that had not been detected in preoperative staging. The study supports the point of view of different centers that an elective neck dissection is either a staging method or in a considerable number of patients a therapy. The only indication to sacrifice the spinal accessory nerve during neck dissection, similary to the hypoglossal nerve, is the certain infiltration by metastases. To ascertain whether there is infiltration of the nerve, it must not be sacrified ,,on principle", but it must be explorativly dissected -and only be resected in case of metastatic infiltration -from the oncologically inconspicuous area to the metastatic area. Most frequently the dissection is carried out in caudocephalad direction, for most cervical metastases occur in the upper third of the neck. The method of uncovering the accessory nerve in the supraclavicular area will be described by the authors.
Our observations for more than 10 years have not shown any difference concerning the frequency of metastatic recurrence in the area of the spinal accessory nerve between preserving and sacrifycing the nerve.
A permanent failure is not to be expected when the nerve is prepared carefully, as done in the surgery of the parotid gland. 
